|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment显示文摘Hepatocellular carcinoma(HCC)is the fifth most common cause of cancer in the world.According to Barcelona Clinic Liver Cancer modified criteria,patients with early stage disease are candidate to radiofrequency ablation(RFA),while patients with intermediate stage HCC are usually treated by transarterial chemoembolization(TACE).TACE and RFA induce a transient devascularisation effect followed by strong neoangiogenic stimulus.In fact,after these procedures,it has been demonstrated an up-regulation of pro-angiogenic and growth factors such as vascular endothelial growth factor-A,which might contribute to accelerated progression in patients with incomplete response.Several studies have demonstrated that MAP-kinase and AKT pathways,in addition to neo-angiogenesis,have an important role in the development of HCC.In advanced HCC,anti-angiogenic therapy and tyrosine kinases inhibitors showed potential clinical benefit.Actually,a number of clinical studies are ongoing testing these agents in combination with TACE or RFA.In this paper,we have reviewed the most recent preclinical and clinical results of such trials. | Girolamo Ranieri Ilaria Marech Vito Lorusso Veronica Goffredo Angelo Paradiso Domenico Ribatti Cosmo Damiano Gadaleta | 2014 | World Journal of Gastroenterology2014，20，2： | 14 |
| 2 | Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients显示文摘AIM: To evaluate vascular endothelial growth factor(VEGF) and tryptase in hepatocellular cancer(HCC)before and after trans-arterial chemoembolization(TACE).METHODS: VEGF and tryptase serum concentrations were assessed from 71 unresectable HCC patients before and after hepatic TACE performed by binding DC-Beads?to doxorubicin. VEGF levels were examined for each serum sample using the Quantikine Human VEGF-enzyme-linked immuno-absorbent assay(ELISA),whereas tryptase serum concentrations were assessed for each serum sample by means of fluoro-enzyme immunoassay(FEIA) using the Uni-CAP100 tool.Differences between serum VEGF and tryptase values before and after TACE were evaluated using Student t test. Person's correlation was used to assess the degree of association between the two variables.RESULTS: VEGF levels and serum tryptase in HCCpatients before TACE had a mean value and standard deviation(SD) of 114.31 ± 79.58 pg/mL and 8.13± 3.61 μg/L, respectively. The mean levels and SD of VEGF levels and serum tryptase in HCC patients after TACE were 238.14 ± 109.41 pg/mL and 4.02 ±3.03 μg/L. The changes between the mean values of concentration of VEGF and tryptase before treatment and after treatment was statistically significant(P <0.000231 and P < 0.00124, by Wilcoxon-Mann-Whitney respectively). A significant correlation between VEGF levels before and after TACE and between tryptase levels before and after TACE was demonstrated(r =0.68, P = 0.003; r = 0.84, P = 0.000 respectively).CONCLUSION: Our pilot results suggest that the higher serum VEGF levels and the lower tryptase levels following TACE may be potential biomarkers changing in response to therapy. | Girolamo Ranieri Michele Ammendola Ilaria Marech Annamaria Laterza Ines Abbate Caroline Oakley Angelo Vacca Rosario Sacco Cosmo Damiano Gadaleta | 2015 | World Journal of Gastroenterology2015，21，19： | 13 |
| 3 | Current trends in management of hepatitis B virus reactivation in the biologic therapy era显示文摘Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk ofHBV reactivation is heightened by the use monoclonalantibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause profound and longlasting immunosuppression. Emerging data indicatethat HBV reactivation could also develop following theuse of other biologic agents, such as tumor necrosis factor (TNF)-α inhibitors. When HBV reactivation is di-agnosed, it is mandatory to suspend biologic treatmentand start antiviral agents immediately. However, preemptive antiviral therapy prior to monoclonal antibodyadministration is crucial in preventing HBV reactivationand its clinical consequences. Several lines of evidencehave shown that risk of HBV reactivation is greatlyreduced by the identifi cation of high-risk patients andthe use of prophylactic antiviral therapy. In this article, we discuss current trends in the management of HBV reactivation in immunosuppressed patients receiving biologic therapy, such as rituximab, alemtuzumab and TNF-α antagonists. | Claudio M Mastroianni Miriam Lichtner Rita Citton Cosmo Del Borgo Angela Rago Helene Martini Giuseppe Cimino Vincenzo Vullo | 2011 | World Journal of Gastroenterology2011，17，34： | 12 |
| 4 | Targeting mast cells in gastric cancer with special reference to bone metastases显示文摘Bone metastases from gastric cancer(GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis. Both primary GC and its metastatic progression rely on angiogenesis. Several lines of evidence from GC patients strongly support the involvement of mast cells(MCs) positive to tryptase(MCPT) in primary gastric tumor angiogenesis. Recently,we analyzed infiltrating MCs and neovascularization in bone tissue metastases from primary GC patients, and observed a significant correlation between infiltrating MCPT and angiogenesis. Such a finding suggested the involvement of peritumoral MCPT by infiltrating surrounding tumor cells, and in bone metastasis angiogenesis from primary GC. Thus, an MCPT-stimulated angiogenic process could support the development of metastases in bone tissue. From this perspective, we aim to review the hypothetical involvement of tumorinfiltrating,peritumoral MCPT in angiogenesis-mediated GC cell growth in the bone microenvironment and in tumor-induced osteoclastic bone resorption. We also focus on the potential use of MCPT targeting agents,such as MCs tryptase inhibitors(gabexate mesylate,nafamostat mesylate) or c-KitR tyrosine kinase inhibitors(imatinib, masitinib), as possible new anti-angiogenic and anti-resorptive strategies for the treatment of GC patientsaffected by bone metastases. | Christian Leporini Michele Ammendola Ilaria Marech Giuseppe Sammarco Rosario Sacco Cosmo Damiano Gadaleta Caroline Oakley Emilio Russo Giovambattista De Sarro Girolamo Ranieri | 2015 | World Journal of Gastroenterology2015，21，37： | 5 |
| 5 | 民营化:英国实践显示文摘 | Cosmo Graham 孟晋(译) 宋华琳(校) | 2006 | 行政法学研究2006，，3： | 3 |
| 6 | Endoscopic submucosal dissection in the treatment of gastric submucosal tumors: results from a retrospective cohort study显示文摘 | Filippo Catalano Luca Rodella Francesco Lombardo Marco Silano Anna Tomezzoli Arnaldo Fuini Maria Antonietta Cosmo Giovanni Manzoni Antonello Trecca | 2013 | Gastric Cancer2013，，4： | 3 |
| 7 | G eant 4—a simulation toolkit显示文摘 | S. Agostinelli J. Allison K. Amako J. Apostolakis H. Araujo P. Arce M. Asai D. Axen S. Banerjee G. Barrand F. Behner L. Bellagamba J. Boudreau L. Broglia A. Brunengo H. Burkhardt S. Chauvie J. Chuma R. Chytracek G. Cooperman G. Cosmo P. Degtyarenko A. Del | 2003 | and Methods in Physics Research, A2003，，3： | 3 |
| 8 | Potential role of Limosilactobacillus fermentum as a probiotic with anti-diabetic properties: A review显示文摘Oxidative stress,inflammation,and gut microbiota impairments have been implicated in the development and maintenance of diabetes mellitus.Strategies capable of recovering the community of commensal gut microbiota and controlling diabetes mellitus have increased in recent years.Some lactobacilli strains have an antioxidant and anti-inflammatory system capable of protecting against oxidative stress,inflammation,and diabetes mellitus.Experimental studies and some clinical trials have demonstrated that Limosilactobacillus fermentum strains can beneficially modulate the host antioxidant and anti-inflammatory system,resulting in the amelioration of glucose homeostasis in diabetic conditions.This review presents and discusses the currently available studies on the identification of Limosilactobacillus fermentum strains with anti-diabetic properties,their sources,range of dosage,and the intervention time in experiments with animals and clinical trials.This review strives to serve as a relevant and well-cataloged reference of Limosilactobacillus fermentum strains capable of inducing anti-diabetic effects and promoting health benefits. | Diego Cabral Lacerda Paulo César Trindade da Costa Paula Brielle Pontes Lucas Alves Carneiro dos Santos JoséPatrocínio Ribeiro Cruz Neto Cristiane Cosmo Silva Luis Vanessa Polyana de Sousa Brito JoséLuiz de Brito Alves | 2022 | World Journal of Diabetes2022，13，9： | 3 |
| 9 | Possible biological and translational significance of mast cells density in colorectal cancer显示文摘Mast cells(MCs), located ubiquitously near blood vessels, are descended from CD34+ hematopoietic stem cells. Initially, although their role has been well defined in hypersensitivity reactions, the discovery of their sharing in both innate and adaptive immunity has allowed to redefine their crucial interplay on the regulatory function between inflammatory and tumor cells through the release of mediators granule-associated(mainly tryptase and vascular endothelial growth factor). In particular, in several animal and human malignancies it has been well demonstrated that activated c-Kit receptor(c-KitR) and tryptase(an agonist of the proteinase-activated receptor-2) take pivotal part in tumor angiogenesis after the MCs activation, contributing to tumor cells invasion and metastasis. In this review, we focused on crucial MCs density(MCD) role in colorectal cancer(CRC) development and progression angiogenesis-mediated; then, we will analyze the principal studies that have focused on MCD as possible prognostic factor. Finally, we will consider a possible role of MCD as novel therapeutic target mainly by c-KitR tyrosine kinase inhibitors(imatinib, masitinib) and tryptase inhibitors(gabexate and nafamostat mesylate) with the aim to prevent CRC progression. | Ilaria Marech Michele Ammendola Claudia Gadaleta Nicola Zizzo Caroline Oakley Cosmo Damiano Gadaleta Girolamo Ranieri | 2014 | World Journal of Gastroenterology2014，20，27： | 3 |
| 10 | The nutritional risk in oncology: a study of 1,453 cancer outpatients显示文摘 | Federico Bozzetti Luigi Mariani Salvatore Lo Vullo Maria Amerio Roberto Biffi Riccardo Caccialanza Giovanni Capuano Isabel Correja Luca Cozzaglio Angelo Di Leo Leonardo Di Cosmo Concetta Finocchiaro Cecilia Gavazzi Antonello Giannoni Patrizia Magnanini Gi | 2012 | Supportive Care in Cancer2012，，8： | 2 |
| 11 | Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization 显示文摘 | Guarracino F Penzo D De Cosmo D | 2003 | Eur J Anaesthesiol2003，20，5： | 1 |
| 12 | Design of process parameters for dual phase steel production with strip rolling using the finite-element method显示文摘 | De Cosmo M Galantucci L M Tricarico L | 1999 | Journal of Materials Processing Technology1999，9293，： | 1 |
| 13 | New Genera-tion of Linux Meta-installers显示文摘 | Trezentos P Di Cosmo R Lauriere S | | 0，，： | 1 |
| 14 | Haemodynamic and metabolic changes during major liver resection with age of hepatic total vascular exclusion显示文摘 | De Cosmo GA Adducci E Gualtieri EM | 2000 | Int Surg2000，85，3： | 1 |
| 15 | Epidural infusion of levobupivacaine and sufentanil following thoracotomy显示文摘 | Cosmo G D Congedo E Mascia A | 2007 | Anaesthesia2007，62，10： | 1 |
| 16 | Pharmacokinetic -based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization显示文摘 | Guarracino F Penzo D De Cosmo D | 2003 | Eur J Anaesthesiol2003，20，5： | 1 |
| 17 | Ropivacaine vs levobpivacaine combinedwith sufentanil for epidural analgesia after lung surgery显示文摘 | De Cosmo G Congedo E Lai C | 2008 | Eur J Anaesthesiol2008，25，12： | 1 |
| 18 | Haemodynamic and metabolic changes during major liver resection with use of hepatic total vascular exclusion显示文摘 | De Cosmo GA Adducci E Gualtieri EM | | 0，，： | 1 |
| 19 | Identification of TSH receptor mutations in three families with resistance to TSH显示文摘 | Tonacchera M Di Cosmo C De Marco G | | 0，，： | 1 |
| 20 | Role of rela- tionship between HbAlc, fibrinogen and HDL- cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus显示文摘 | Pacilli A Cosmo S D Trischitta V | 2013 | Atherosclerosis2013，228，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员